Joint Formulary & PAD

Salmeterol (Serevent Evohaler / Serevent Accuhaler) - Asthma

I agree that in using this database I understand that this platform only provides guidance on local prescribing policy and that all prescribing decisions are ultimately the responsibility of the clinician.

Status 1

Non Formulary
Formulations :
  • Inhaler (Metered Dose)
Associated Icons :
Restrictions / Comments :
Important

Serevent Evohaler

LABA monotherapy no longer recommended for asthma or COPD.

Not for initiation in new patients.

 

Status 2

Non Formulary
Formulations :
  • Inhaler (dry powder)
Associated Icons :
Restrictions / Comments :
Important

Serevent Accuhaler

LABA monotherapy no longer recommended for asthma or COPD.

Not for initiation in new patients.

PAD Profile

ChemicalSubstance :
Salmeterol (Serevent Evohaler / Serevent Accuhaler)
Indication :
Asthma
Group Name :
LABA
Keywords :
LABAs, adrenoreceptor agonists, bronchodilators, long acting beta 2 agonist, respiratory, asthmatics, Selective beta2-agonists, long-acting beta agonists
Brand Names Include :
Serevent Evohaler, Serevent Accuhaler, Soltel,
Important Information :
Latest Additions Date From :
Latest Additions Date To :
Guidelines :
Supporting Documents :
9
Traffic Light Entries :
2

Other Indications

Below are listed other indications that Salmeterol (Serevent Evohaler / Serevent Accuhaler) is used to treat.

Other Drugs

Below are listed other drugs that are used to treat Asthma.

Committee Recommendations (1)

Single device LABA is not recommended in Asthma or COPD.
Combined LAMA/LABA is the bronchodilator treatment of choice for patients with COPD who are breathless or having exacerbations following treatment with SABA.

Existing LABA patients, whose symptoms are under control, can continue with their current treatment until both they and their NHS healthcare professional agree it is appropriate to change.

Inhaler devices should be prescribed by BRAND.

See COPD guidelines for more information